Alexion Pharmaceuticals - Archives

2006 Archives

Eculizumab is Well Tolerated and Demonstrates Significant Improvement During 52 Weeks of Treatment in Open-Label Phase III SHEPHERD Study in PNH Patients

Saturday, December 9, 2006
Alexion Pharmaceuticals Soliris(TM) (Eculizumab) data to be Presented at 2006 American Society of Hematology (ASH) Annual Meeting

Friday, December 8, 2006
Alexion to Present at BMO Capital Markets Focus on Healthcare Conference

Wednesday, November 29, 2006
Alexion To Present At Piper Jaffray 18th Annual Health Care Conference

Wednesday, November 22, 2006
Alexion Pharmaceuticals Announces Closing of Public Offering of Stock

Tuesday, November 21, 2006
Alexion Pharmaceuticals Announces Proposed Public Offering of Common Stock

Tuesday, November 14, 2006
FDA Grants Priority Review for Soliris(TM) (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria

Tuesday, November 14, 2006
Alexion to Present at the 2006 Credit Suisse Healthcare Conference

Friday, November 10, 2006
Alexion Pharmaceuticals Soliris(TM) (Eculizumab) Data to be Presented at 2006 American Society of Hematology (ASH) Annual Meeting

Thursday, November 9, 2006
Alexion to Present At Cowen and Company 7th Annual Global Health Care Conference

Friday, November 3, 2006
Alexion Pharmaceuticals Reports Third Quarter 2006 Results

Wednesday, November 1, 2006
Alexion Pharmaceuticals Invites You to Participate in its Third Quarter Results Conference Call and Web Cast

Friday, October 13, 2006
Alexion Submits Market Authorization Application for Soliris(TM) (eculizumab) in the Treatment of Paroxysmal Nocturnal Hemoglobinuria to the European Medicines Agency

Tuesday, September 26, 2006
Alexion Pharmaceuticals Submits Biologics License Application for Soliris(TM) (eculizumab)

Wednesday, September 20, 2006
Soliris(TM) (eculizumab) Demonstrates Significant Improvement in PNH Study

Wednesday, September 20, 2006
Alexion To Present At UBS Global Life Sciences Conference

Monday, September 18, 2006
Alexion to Present at Bear Stearns healthcare Conference

Tuesday, September 5, 2006
Alexion Pharmaceuticals Reports Second Quarter 2006 Results

Tuesday, August 8, 2006
Alexion Pharmaceuticals Invites You to Participate in its Second Quarter Results Conference Call and Web Cast

Tuesday, July 25, 2006
Alexion Pharmaceuticals Purchases Biopharmaceutical Manufacturing Site in Rhode Island

Thursday, July 13, 2006
Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations

Thursday, July 6, 2006
Alexion Announces the EXPLORE Clinical Diagnostic Study for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Friday, June 16, 2006
Alexion Pharmaceuticals Reports Positive Interim Safety and Efficacy Results for Soliris(TM) (eculizumab) From the Open-Label Phase III SHEPHERD Safety Trial in Paroxysmal Nocturnal Hemoglobinuria Patients

Monday, June 12, 2006
ALEXION Announces Pre-Clinical Results with Novel Anti-Cancer Antibody; Treatment Against New Potential Cancer Target Found to Stop Leukemia Tumor Growth

Tuesday, June 6, 2006
ALEXION Pharmaceuticals™ Antibody Therapy Shown Effective in Model for Severe Allergic Asthma

Saturday, May 13, 2006
ALEXION Pharmaceuticals Reports First Quarter 2006 Results

Thursday, April 27, 2006
Alexion To Present At Investor Conferences

Tuesday, April 25, 2006
Alexion Pharmaceuticals Invites You to Participate in its First Quarter Results Conference Call and Web Cast

Thursday, April 13, 2006
ALEXION To Present At Cowen & Co. 26th Annual Health Care Conference

Monday, February 27, 2006
ALEXION To Present At The Citigroup 2006 Healthcare Conference

Tuesday, February 21, 2006
Alexion Pharmaceuticals Reports 2005 Financial Results and 2006 Outlook

Tuesday, February 14, 2006